Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature

In patients undergoing debulking surgery for ovarian cancer (OC), bevacizumab-combined chemotherapy has been reported to be associated with an increased incidence of adverse events (AEs). Reports in the literature have noted the overall morbidity of bevacizumab to be between 3.7% and 9%. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Turco, Luigi Carlo, Ferrandina, Gabriella, Vargiu, Virginia, Cappuccio, Serena, Fagotti, Anna, Sallustio, Giuseppina, Scambia, Giovanni, Cosentino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812204/
https://www.ncbi.nlm.nih.gov/pubmed/33490199
http://dx.doi.org/10.21037/atm-20-4448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812204/
https://www.ncbi.nlm.nih.gov/pubmed/33490199
http://dx.doi.org/10.21037/atm-20-4448

Ejemplares similares